Anti-tumor applications of activating toll-like receptor 9 with PF-3512676 (formerly CPG 7909)

被引：0
|
作者：
Krieg, Arthur M. [1 ]
机构：
[1] Coley Pharmaceut Grp, Wellesley, MA USA
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 06期
关键词：
D O I：
10.1016/j.ejcsup.2006.04.031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S30
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [1] CPG-7909 (PF-3512676, ProMune®):: toll-like receptor-9 agonist in cancer therapy
    Murad, Yanal M.
    Clay, Timothy M.
    Lyerly, H. Kim
    Morse, Michael A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (08) : 1257 - 1266
  • [2] PF-3512676 (CPG 7909), a toll-like receptor 9 agonist-status of development for non-small cell lung cancer (NSCLC)
    Readett, David R.
    Denis, Louis J.
    Krieg, Arthur M.
    Benner, Rebecca J.
    Hanson, Donald C.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S461 - S461
  • [3] Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
    Kim, Youn H.
    Girardi, Michael
    Duvic, Madeleine
    Kuzel, Timothy
    Link, Brian K.
    Brown, Lauren Pinter
    Rook, Alain H.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 63 (06) : 975 - 983
  • [4] Early development of the Toll-like receptor 9 agonist PF-3512676, for the treatment of patients with advanced cancers
    Tarhini, Ahmad A.
    Kirkwood, John M.
    Krieg, Arthur M.
    EXPERT OPINION ON DRUG DISCOVERY, 2009, 4 (05) : 587 - 603
  • [5] Toll-like-receptor 9 (TLR-9) agonist PF-3512676 (CPG 7909) in combination with chemotherapy in the treatment of non-small cell lung cancer (NSCLC)
    Gauler, T.
    Schuett, P.
    Eberhardt, W.
    ANNALS OF ONCOLOGY, 2007, 18 : 24 - 25
  • [6] Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer
    Belani, Chandra P.
    Nemunaitis, John J.
    Chachoua, Abraham
    Eisenberg, Peter D.
    Raez, Luiz E.
    Cuevas, J. Daniel
    Mather, Cecile B.
    Benner, Rebecca J.
    Meech, Sandra J.
    CANCER BIOLOGY & THERAPY, 2013, 14 (07) : 557 - 563
  • [7] Autologous tumor cell vaccination with PF-3512676 (CPG 7909) and GM-CSF followed by subcutaneous PF-3512676 and IFN-alpha for patients with metastatic renal cell carcinoma.
    Van den Eertwegh, A. J.
    Lensen, R. J.
    Scheper, R. J.
    Giaccone, G.
    Meijer, C. J.
    Bontkes, H. J.
    Gruijl, T. D.
    Hooijberg, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 107S - 107S
  • [8] The TLR9 agonist PF-3512676 (Formerly CPG 7909) induces T cell-mediated tumor regression synergistically with paclitaxel or treg depletion in a metastatic murine cancer model
    Weeratna, Risini D.
    Vicari, Alain P.
    Bourne, Liana
    Davis, Heather L.
    Krieg, Arthur
    JOURNAL OF IMMUNOTHERAPY, 2006, 29 (06) : 678 - 679
  • [9] RANDOMIZED PHASE II TRIAL OF ERLOTINIB WITH OR WITHOUT PF-3512676 (CPG 7909, A TOLL-LIKE RECEPTOR 9 [TLR9] AGONIST) IN PATIENTS WITH ADVANCED RECURRENT EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Belani, Chandra P.
    Nemunaitis, John J.
    Chachoua, Abraham
    Eisenberg, Peter D.
    Raez, Luis E.
    Cuevas, Juan D.
    Mather, Cecile B.
    Benner, Rebecca J.
    Meech, Sandra J.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1218 - S1219
  • [10] Antitumor applications of stimulating Toll-like receptor 9 with CpG oligodeoxynucleotides
    Krieg A.M.
    Current Oncology Reports, 2004, 6 (2) : 88 - 95
12345